Anti-HIV Agents - Adverse effects
Research News and Information

Monday, November 23, 2009

Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection.

30 Oct 2009 OBJECTIVES: The purpose of this study was to evaluate the safety and efficacy of raltegravir vs efavirenz-based antiretroviral therapy after 96 weeks in treatment-naive patients with HIV-1 infection. METHODS: Multicenter, double-blind, randomized ... Read more...

Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.

13 Oct 2009 BACKGROUND: Among patients with multidrug-resistant human immunodeficiency virus type 1 (HIV-1) infection, salvage regimens including enfuvirtide have demonstrated sustained efficacy. Because of reluctance to use subcutaneous injections, raltegravir ... Read more...

Cardiovascular risk assessment in antiretroviral-naïve HIV patients.

29 Sep 2009 Various studies have been conducted to evaluate the role of antiretroviral therapy in the onset of cardiovascular risk among HIV-1-infected patients, while fewer data are available regarding antiretroviral-naïve patients. Our objective was to ... Read more...

Latest indexed articles for 'Anti-HIV Agents - Adverse effects'

These are the very latest articles for this heading:

• Nanotechnology for antiretroviral drug delivery. 29 Nov 2009
• Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. 30 Oct 2009
• Clinical practice. Postexposure prophylaxis for HIV infection. 27 Oct 2009
• Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial. 13 Oct 2009
• Cardiovascular risk assessment in antiretroviral-naïve HIV patients. 29 Sep 2009
• Long-term combination antiretroviral therapy is associated with the risk of coronary plaques in African Americans with HIV infection. 29 Sep 2009
• New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir. 29 Sep 2009
• Assessment of neuropathic pain in primary care. 29 Sep 2009
• Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: a prospective multicenter study. 13 Sep 2009
• Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA). 13 Sep 2009
• The nucleoside analogue D-carba T blocks HIV-1 reverse transcription. 8 Sep 2009
• Efficacy and safety of atazanavir-ritonavir plus abacavir-lamivudine or tenofovir-emtricitabine in patients with hyperlipidaemia switched from a stable protease inhibitor-based regimen including one thymidine analogue. 30 Aug 2009
• [Tenofovir, An antiviral agent with activity against HIV infections and hepatitis B.] 30 Aug 2009
• Exercise: the best therapy for managing side effects. How to stay active and energetic. 30 Aug 2009
• Queaze, sneeze, yawn, and runs. A little laundry list of possible side effects of the different HIV drug classes. 30 Aug 2009
• Are we meeting the American Diabetes Association goals for HIV-infected patients with diabetes mellitus? 30 Aug 2009
• Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. 30 Aug 2009
• Renal impairment in a rural African antiretroviral programme. 26 Aug 2009
• Protein-losing enteropathy during highly active antiretroviral therapy in a patient with AIDS-related disseminated Mycobacterial avium complex infection. 16 Aug 2009
• Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. 13 Aug 2009

See a longer list of these articles.

Technical information about 'Anti-HIV Agents'

Definition: Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.

Registry Number: 0

Descriptor UI: D019380

Alternative terms: Anti-HIV Agents; Agents, Anti-HIV; Anti HIV Agents; Anti-HIV Drugs; Anti HIV Drugs; Drugs, Anti-HIV; AIDS Drugs; Drugs, AIDS; Anti-AIDS Agents; Agents, Anti-AIDS; Anti AIDS Agents; Anti-AIDS Drugs; Anti AIDS Drugs; Drugs, Anti-AIDS;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.954.122.388.077.088;

History Note: 97

Technical Notes: consider also AIDS /drug ther; may be used for articles on simian acquired immunodefic syndrome & simian immunodefic virus